Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW4902 in patients with uterine fibroids
NCT07319520Phase 2Completed
- Sponsor
- Daewon Pharm
- Start
- Oct 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of merigolix in Uterine Fibroids (UF), sponsored by Daewon Pharm. Primary endpoint: Pictorial Blood Loss Assessment Chart. Started Oct 2021; status: completed.
02
Drugs
merigolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT07319520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319520.